Diphenylpyraline

Jump to: navigation, search
Diphenylpyraline
Diphenylpyraline.png
Clinical data
Synonyms4-(diphenylmethoxy)-1-methyl-piperidine
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral, Topical
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life24-40 hours[1]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H23NO
Molar mass281.392 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Diphenylpyraline

Articles

Most recent articles on Diphenylpyraline

Most cited articles on Diphenylpyraline

Review articles on Diphenylpyraline

Articles on Diphenylpyraline in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Diphenylpyraline

Images of Diphenylpyraline

Photos of Diphenylpyraline

Podcasts & MP3s on Diphenylpyraline

Videos on Diphenylpyraline

Evidence Based Medicine

Cochrane Collaboration on Diphenylpyraline

Bandolier on Diphenylpyraline

TRIP on Diphenylpyraline

Clinical Trials

Ongoing Trials on Diphenylpyraline at Clinical Trials.gov

Trial results on Diphenylpyraline

Clinical Trials on Diphenylpyraline at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Diphenylpyraline

NICE Guidance on Diphenylpyraline

NHS PRODIGY Guidance

FDA on Diphenylpyraline

CDC on Diphenylpyraline

Books

Books on Diphenylpyraline

News

Diphenylpyraline in the news

Be alerted to news on Diphenylpyraline

News trends on Diphenylpyraline

Commentary

Blogs on Diphenylpyraline

Definitions

Definitions of Diphenylpyraline

Patient Resources / Community

Patient resources on Diphenylpyraline

Discussion groups on Diphenylpyraline

Patient Handouts on Diphenylpyraline

Directions to Hospitals Treating Diphenylpyraline

Risk calculators and risk factors for Diphenylpyraline

Healthcare Provider Resources

Symptoms of Diphenylpyraline

Causes & Risk Factors for Diphenylpyraline

Diagnostic studies for Diphenylpyraline

Treatment of Diphenylpyraline

Continuing Medical Education (CME)

CME Programs on Diphenylpyraline

International

Diphenylpyraline en Espanol

Diphenylpyraline en Francais

Business

Diphenylpyraline in the Marketplace

Patents on Diphenylpyraline

Experimental / Informatics

List of terms related to Diphenylpyraline

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenylpiperidine class.[2][3][4] It is marketed in Europe for the treatment of allergies.[2][3][5] DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents.[6] It has been shown to be useful in the treatment of Parkinsonism.[7]

Chemistry

Diphenylpyraline, 4-diphenylmethoxy-1-methylpiperidine, is synthesized by alkylating 4-hydroxy-1-methylpiperidine with benzhydrylbromide.

Diphenylpyraline synthesis.png

See also

References

  1. Graham G, Bolt AG (June 1974). "Half-life of diphenylpyraline in man". Journal of Pharmacokinetics and Biopharmaceutics. 2 (3): 191–5. doi:10.1007/BF01059761. PMID 4156058.
  2. 2.0 2.1 Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  3. 3.0 3.1 Puhakka H, Rantanen T, Virolainen E (1977). "Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis". J Int Med Res. 5 (1): 37–41. PMID 14039.
  4. Kubo N, Shirakawa O, Kuno T, Tanaka C (March 1987). "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay". Japanese Journal of Pharmacology. 43 (3): 277–82. doi:10.1254/jjp.43.277. PMID 2884340.
  5. Hruby, Victor J.; Ruben Vardanyan; Vardanyan, ۊRuben (2006). Synthesis of essential drugs. Amsterdam: Elsevier. ISBN 0-444-52166-6.
  6. Lapa G, Mathews T, Harp J, Budygin E, Jones S (2005). "Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties". Eur J Pharmacol. 506 (3): 237–40. doi:10.1016/j.ejphar.2004.11.017. PMID 15627433.
  7. Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001). "Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients". J Neurol Sci. 182 (2): 95–7. doi:10.1016/S0022-510X(00)00441-X. PMID 11137513.